The Role of CDK4 in the Pathogenesis of Pancreatic Cancer

by Emily Jiggens, Maria Mortoglou, Guy H. Grant, Pinar Uysal-Onganer
Published 2021

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

by Irina V. Kolyadina, Natalia R. Abidova, Arshak A. Akopyan, Galina V. Antonova, Oksana I. Arapova, Elvira A. Bobrova, Larisa V. Bolotina, Chulpan K. Valiakhmetova, Anna V. Vasilevskaya, Lyubov Y. Vladimirova, Mikhail V. Volkonskiy, Inna P. Ganshina, Irina E. Gudkova, Alexandr S. Dergunov, Irina V. Evstigneeva, Viktoria S. Egurenkova, Aleksei V. Emshanov, Lyudmila G. Zhukova, Elena V. Zueva, Elena V. Karabina, James J. Kolokolov, Svetlana V. Kuzmicheva, Olesya A. Kuchevskaya, Ivan A. Luev, Ksenia S. Maistrenko, Elena V. Markizova, Vasily V. Marfutov, Sergey P. Medvedev, Yulia I. Merzlikina, Tatyana A. Nersesova, Elena G. Ovchinnikova, Svetlana A. Orlova, Natalia Y. Samaneva, Olesya A. Stativko, Anna E. Storozhakova, Daniil L. Stroyakovskiy, Alexander V. Sultanbaev, Asiat I. Tekeeva, Natalia V. Fadeeva, Alina N. Fedorova, Oksana M. Shalaeva, Irina A. Shangina, Oksana N. Shirokova, Alisa R. Shumskikh, Mariam Z. Yakubova
Published 2021

Surgery to Oligometastatic Breast Cancer after Excellent Response to Palbociclib and Letrozole Therapy: Pitfall of Ultrasound Therapeutic Evaluation

by Suzuka Fujii, Shoji Oura, Shinichiro Makimoto
Published 2021

Učinkovitost in najpogostejši neželeni učinki zdravljenja z zaviralci od ciklina odvisnih kinaz 4 in 6 (CDK 4/6) pri metastatskem raku dojke

by Nina Privšek, Cvetka Grašič Kuhar
Published 2021

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies

by Abeer J. Al-Qasem, Carla L. Alves, Henrik J. Ditzel
Published 2021

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer

by Erin R. Scheidemann, Ayesha N. Shajahan-Haq
Published 2021

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement

by Naiba Nabieva, Peter A. Fasching
Published 2021

FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells

by Qiong Cheng, Zhikun Ma, Yujie Shi, Amanda B. Parris, Lingfei Kong, Xiaohe Yang
Published 2021

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first e...

by Irina V. Kolyadina, Inna P. Ganshina, Svetlana V. Kuzmicheva, Asiiat I. Tekeeva, James D. Kolokolov, Mikhail V. Volkonskii, Irina V. Poddubnaya
Published 2020

Genomic analyses of high‐grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities

by Haider Mahdi, Amy Joehlin‐Price, Esther Elishaev, Afshin Dowlati, Ata Abbas
Published 2021

Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast C...

by Editorial Board
Published 2021

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib

by Edessa D, Sisay M
Published 2017

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer

by Board Editorial
Published 2021